Role of octreodite in the management of patients with cancer

Current Oncology

Volumn 10, Issue 3, 2003, Pages 161-179

  Major, Pierre ^a   Figueredo, A ^b   Tandan, V ^b   Bramwell, V ^b   Charette, M ^b   Oliver, T ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; FOLINIC ACID; LOPERAMIDE; OCTREOTIDE; QUINAGOLIDE; SCOPOLAMINE BUTYL BROMIDE; TAMOXIFEN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADVANCED CANCER; BREAST METASTASIS; CANCER HORMONE THERAPY; CARCINOID; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG MEGADOSE; ESOPHAGUS VARICES BLEEDING; HORMONE RELEASE; HUMAN; HYPERBILIRUBINEMIA; INJECTION PAIN; INJECTION SITE; INTESTINE OBSTRUCTION; META ANALYSIS; NAUSEA; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PANCREAS SURGERY; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREOPERATIVE TREATMENT; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; STEATORRHEA; TERMINAL DISEASE; VOMITING;

EID: 1542377409     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. de Herder WW, van der Lely AJ, Lamberts SW. Somatostatin analogue treatment of neuroendocrine tumours. Postgrad Med J 1996;72:403-8.
2. Schally AV. Oncological applications of somatostatin analogues. Cancer Res 1988;48:6977-85.
3. Browman GP, Levine MN, Mohide EA, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995;13:502-12.
4. Wadler S, Benson AB 3rd, Engelking C, et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 1998;16:3169-78.
5. Harris AG, O'Dorisio TM, Woltering EA, et al. Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel. Dig Dis Sci 1995;40:1464-73.
6. Goumas P, Naxakis S, Christopoulou A, Chrysanthopoulos C, Nikolopoulou V, Kalofonos H. Octreotide acetate in the treatment of fluorouracil-induced diarrhea. Oncologist 1998;3:50-3.
7. Geller RB, Gilmore CE, Dix SP, et al. Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients. Am J Hematol 1995;50:167-72.
8. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Control of chemotherapy-induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin. Oncology 1994;51:70-3.
9. Nikou GC, Polyzos A, Kostalas G, et al. Octreotide administration and gut hormone levels in patients with chemotherapy-induced diarrhea. Hellenic J Gastroenterol 1994;7:111-4.
10. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 1993;11:148-51.
11. Gebbia V, Carreca I, Testa A, et al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 1993;4:443-5.
12. Montorsi M, Zago M, Mosca F, et al. Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial. Surgery 1995;117:26-31.
13. Bassi CI, Falconi M, Lombardi D, et al. Prophylaxis of complications after pancreatic surgery: results of a multicenter trial in Italy. Digestion 1994;55:41-7.
14. Friess H, Klempa I, Hermanek P, et al. Prophylaxis of complications after pancreatic surgery: results of a multicenter trial in Germany. Digestion 1994;55:35-40.
15. Saslow SB, O'Brien MD, Camilleri M, et al. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome. Am J Gastroenterol 1997;92:2250-6.
16. Jacobsen MB, Hanssen LE. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial. J Intern Med 1995;237:269-75.
17. Öberg K, Norheim I, Theodorsson E, Ahlman H, Lundqvist C, Wide L. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome. J Clin Endrocinol Metab 1989;68:796-800.
18. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999;17:600-6.
19. O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000;88:770-6.
20. Harris AG, Redfern JS. Octreotide treatment of carcinoid syndrome: analysis of published dose-titration data. Aliment Pharmacol Ther 1995;9:387-94.
21. Tomassetti P, Migliori M, Corinaldesi R, Gullo L. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 2000;14:557-60.
22. Angeletti S, Corleto VD, Schillaci O, et al. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours. Ital J Gastroenterol Hepatol 1999;31:23-7.
23. Frank M, Klose K, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and α-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999;94:1381-7.
24. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996;38:430-8.
25. Bordi C, Azzoni C, Pilato FP, et al. Morphometry of gastric endocrine cells in hypergastrinemic patients treated with the somatostatin analogue octreotide. Regul Pept 1993;47:307-18.
26. Eriksson B, Öberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993;32:203-8.
27. Cho KJ, Vinik AI. Effect of somatostatin analogue (octreotide) on blood flow to endocrine tumors metastatic to the liver: angiographic evaluation. Radiology 1990;177:549-53.
28. Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Öberg K. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990;65:1883-90.
29. Wynick D, Anderson JV, Williams SJ, Bloom SR. Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995). Clin Endocrinol 1989;30:385-8.
30. Eriksson B, Öberg K, Andersson T, Lundqvist G, Wide L, Wilander E. Treatment of malignant endocrine pancreatic tumors with a new long-acting somatostatin analogue, SMS 201-995. Scand J Gastroenterol 1988;23:508-12.
31. Vinik AI, Tsai S, Moattari AR, Cheung P. Somatostatin analogue (SMS 201-995) in patients with gastrinomas. Surgery 1988;104:834-42.
32. Kvols LK, Buck M, Moertel CG, et al. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med 1987;107:162-8.
33. Souquet JC, Sassolas G, Forichon J, Champetier P, Partensky C, Chayvialle JA. Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome. Cancer 1987;59:1654-60.
34. Ch'ng JLC, Anderson JV, Williams SJ, Carr DH, Bloom SR. Remission of symptoms during long term treatment of metastatic pancreatic endocrine tumours with long acting somatostatin analogue. Br Med J (Clin Res Ed) 1986;292:981-2.
35. Wood SM, Kraenzlin ME, Adrian TE, Bloom SR. Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses. Gut 1985;26:438-44.
36. Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 2000;8:188-91.
37. Ripamonti C, Mercadante S, Groff L, Zecca E, De Cono F, Casuccio A. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage 2000;19:23-34.
38. Mangili G, Franchi M, Mariani A, et al. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol 1996;61:345-8.
39. Khoo D, Hall E, Motson R, Riley J, Denman K, Waxman J. Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer 1994;30:28-30.
40. Mercadante S, Caraceni A, Simonetti MT. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med 1993;7:295-9.
41. Bajetta E, Procopio G, Ferrari L, et al. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer 2002;94:299-304.
42. Ingle JN, Suman VJ, Kardinal CG, et al. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 1999;85:1284-92.
43. Bontenbal M, Foekens JA, Lamberts SWJ, et al. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up. Br J Cancer 1998;77:115-22.
44. Burch PA, Block M, Schroeder G, et al. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study. Clin Cancer Res 2000;6:3486-92.
45. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut 1998;42:442-7.
46. Pederzoli P, Maurer U, Vollmer K, et al. Phase 3 trial of SMS 201-995 pa LAR (SMS pa LAR) VS. placebo in unresectable stage II, III and IV pancreatic cancer [abstract 988]. Proc Am Soc Clin Oncol 1998;17:257a.
47. Roy A, Jacobs A, Bukowski R, et al. Phase 3 trial of SMS 201-995 pa LAR (SMS pa LAR) and continuous infusion (CI) 5-FU in unresectable stage II, III, and IV pancreatic cancer [abstract 987]. Proc Am Soc Clin Oncol 1998;17:257.
48. Cascinu S, Del Ferro E, Catalano G. A randomized trial of octreotide vs. best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer 1995;71:97-101.
49. Goldberg RM, Moertel CG, Wieand HS, et al. A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. Cancer 1995;76:961-6.
50. Bryant JL, Smith R, Margolese R, et al. Increased gallbladder adverse events associated with octreotide pa LAR in patients with breast cancer [abstract 197]. Proc Am Soc Clin Oncol 2001;20:50A.
51. Pollak M, Pritchard K, Whelan T, et al. The NCIC CTG MA. 14 experience with the gallbladder toxicity of octreotide pamoate (ONCOLAR) in a postmenopausal patient population undergoing adjuvant treatment for stage 1-3 breast cancer. Eur J Cancer 2002;38(suppl 3):s2-179.